Vasopressin 2 Units/2 mL in 0.9% Sodium Chloride Sterile Syringe for Injection, Concentration: 1 ...
FDA Drug Recall #D-0325-2024 — Class II — January 22, 2024
Recall Summary
| Recall Number | D-0325-2024 |
| Classification | Class II — Moderate risk |
| Date Initiated | January 22, 2024 |
| Status | Ongoing |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | IntegraDose Compounding Services LLC |
| Location | Minneapolis, MN |
| Product Type | Drugs |
| Quantity | 1,299 syringes |
Product Description
Vasopressin 2 Units/2 mL in 0.9% Sodium Chloride Sterile Syringe for Injection, Concentration: 1 Unit/mL, 2 mL Syringe, Rx Only, 719 Kasota Ave SE, Minneapolis, MN, Compounded Drug Not for Resale. Office Use Only, NDC 71139-0190-1.
Reason for Recall
Sub-potent drug: failure to maintain potency through the duration of the labeled expiration/beyond-use date.
Distribution Pattern
MN
Lot / Code Information
Lot #s: 20230929VAS-2, Exp. 02/29/2024; 20231004VAS-2, Exp. 04/01/2024; Lot 20231010VAS-2,Exp. 04/07/2024; Lot 20231013VAS-2, Exp. 04/10/2024
Other Recalls from IntegraDose Compounding Services LLC
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0015-2026 | Class I | Oxytocin 30 Units/500 mL in 0.9% Sodium Chlorid... | Sep 16, 2025 |
| D-0432-2024 | Class II | fentaNYL Citrate 2,500 mcg/50mL in Sterile Wate... | Mar 22, 2024 |
| D-0258-2024 | Class II | Vasopressin 2 Unit/2 mL in 0.9% Sodium Chloride... | Jan 12, 2024 |
| D-0896-2021 | Class II | ceFAZolin, 2 G/20 mL in Sterile Water, 20 mL St... | Sep 17, 2021 |
| D-0897-2021 | Class II | ceFAZolin 3 G in 0.9% Sodium Chloride, 115 mL B... | Sep 17, 2021 |
Frequently Asked Questions
Stop using the medication immediately and contact your pharmacist. A mislabeling recall can range from a minor technical error (wrong font size) to a serious mix-up where one drug is inside another drug's packaging. If you received a medication that looks or acts differently than expected, or if you experienced unexpected effects, tell your doctor immediately. The pharmacist can verify whether your specific lot is affected and provide a replacement. Report any adverse effects experienced to FDA MedWatch at 1-800-FDA-1088.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.